Deintensification of radiotherapy in oropharyngeal carcinoma of squamous cells.
Abstract
The human papilloma virus (HPV) has been associated with oropharyngeal squamous cell carcinoma (OSCC) for 35 years, however there are many characteristics that differentiate both pathologies......
References
[1]. WHO. WHO Classification of Head and Neck Tumours. Vol. 9. 4ta ed. WHO; 2017. https://www.iarc.who.int/news-events/who-classification-of-head-and-neck-tumours/
[2]. Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016 Mar;91(3):386-96. doi: 10.1016/j.mayocp.2015.12.017. PMID: 26944243.
[3]. Liu C, Mann D, Sinha UK, Kokot NC. The molecular mechanisms of increased radiosensitivity of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC): an extensive review. J Otolaryngol Head Neck Surg. 2018 Sep 21;47(1):59. doi: 10.1186/s40463-018-0302-y. PMID: 30241572; PMCID: PMC6150985.
[4]. Mirghani H, Amen F, Tao Y, Deutsch E, Levy A. Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives. Cancer Treat Rev. 2015 Dec;41(10):844-52. doi: 10.1016/j.ctrv.2015.10.001. PMID: 26476574.
[5]. Amin MB, Edge SB, AJCC. AJCC Cancer Staging Manual. 8va edición. Switzerland Springer; 2017.
[6]. NCCN. National Comprehensive Cancer Network. Head and Neck Cancer. Versión 2. 2020.
[7]. Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? Am Soc Clin Oncol Educ Book. 2019 Jan;39:364-372. doi: 10.1200/EDBK_238315. PMID: 31099643.
[8]. Durkova J, Boldis M, Kovacova S. Has the time come for de-escalation in the management of oropharyngeal carcinoma? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Dec;163(4):293-301. doi: 10.5507/bp.2019.059. PMID: 31796941.
[9]. Clinicaltrials.gov. [Internet] EE.UU: clinicaltrials.gov. Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer. Disponible en: https://clinicaltrials.gov/ct2/show/NCT02254278.
[10]. Clinicaltrials.gov. [Internet] EE.UU: clinicaltrials.gov. The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer Disponible en: https://clinicaltrials.gov/ct2/show/NCT01706939?term=quarterback&draw=2&rank=2.
[11]. Clinicaltrials.gov. [Internet] EE.UU: clinicaltrials.gov. [actualizado el 12.08.20, consultado el 22.10.20]. Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal CancerDisponible en: https://www.clinicaltrials.gov/ct2/show/NCT03224000.
[12]. Qureishi A, Mawby T, Fraser L, Shah KA, Møller H, Winter S. Current and future techniques for human papilloma virus (HPV) testing in oropharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2017 Jul;274(7):2675-2683. doi: 10.1007/s00405-017-4503-1. PMID: 28285422.
[13]. Hayes DN, Van Waes C, Seiwert TY. Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. J Clin Oncol. 2015 Oct 10;33(29):3227-34. doi: 10.1200/JCO.2015.62.1086. PMID: 26351353; PMCID: PMC4586167.
[14]. DIPRECE. Plan nacional de prevención y control del VIH/SIDA e ITS. [Internet] Vol. 1. 1ra ed. Santiago, Chile, 2018. Disponible en: https://diprece.minsal.cl/wp-content/uploads/2019/06/2019.06.12_PLAN-NACIONAL-VIH-SIDA-E-ITS.pdf.
[15]. INJUV. Novena Encuesta nacional de juventud 2018. [Internet] Vol 1., 1ra ed. Santiago, Chile; 2019. Disponible en: http://www.injuv.gob.cl/storage/docs/9%C2%B0_Encuesta_Nacional_de_Juventud_2018.pdf.
[2]. Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016 Mar;91(3):386-96. doi: 10.1016/j.mayocp.2015.12.017. PMID: 26944243.
[3]. Liu C, Mann D, Sinha UK, Kokot NC. The molecular mechanisms of increased radiosensitivity of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC): an extensive review. J Otolaryngol Head Neck Surg. 2018 Sep 21;47(1):59. doi: 10.1186/s40463-018-0302-y. PMID: 30241572; PMCID: PMC6150985.
[4]. Mirghani H, Amen F, Tao Y, Deutsch E, Levy A. Increased radiosensitivity of HPV-positive head and neck cancers: Molecular basis and therapeutic perspectives. Cancer Treat Rev. 2015 Dec;41(10):844-52. doi: 10.1016/j.ctrv.2015.10.001. PMID: 26476574.
[5]. Amin MB, Edge SB, AJCC. AJCC Cancer Staging Manual. 8va edición. Switzerland Springer; 2017.
[6]. NCCN. National Comprehensive Cancer Network. Head and Neck Cancer. Versión 2. 2020.
[7]. Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? Am Soc Clin Oncol Educ Book. 2019 Jan;39:364-372. doi: 10.1200/EDBK_238315. PMID: 31099643.
[8]. Durkova J, Boldis M, Kovacova S. Has the time come for de-escalation in the management of oropharyngeal carcinoma? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019 Dec;163(4):293-301. doi: 10.5507/bp.2019.059. PMID: 31796941.
[9]. Clinicaltrials.gov. [Internet] EE.UU: clinicaltrials.gov. Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer. Disponible en: https://clinicaltrials.gov/ct2/show/NCT02254278.
[10]. Clinicaltrials.gov. [Internet] EE.UU: clinicaltrials.gov. The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer Disponible en: https://clinicaltrials.gov/ct2/show/NCT01706939?term=quarterback&draw=2&rank=2.
[11]. Clinicaltrials.gov. [Internet] EE.UU: clinicaltrials.gov. [actualizado el 12.08.20, consultado el 22.10.20]. Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal CancerDisponible en: https://www.clinicaltrials.gov/ct2/show/NCT03224000.
[12]. Qureishi A, Mawby T, Fraser L, Shah KA, Møller H, Winter S. Current and future techniques for human papilloma virus (HPV) testing in oropharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2017 Jul;274(7):2675-2683. doi: 10.1007/s00405-017-4503-1. PMID: 28285422.
[13]. Hayes DN, Van Waes C, Seiwert TY. Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. J Clin Oncol. 2015 Oct 10;33(29):3227-34. doi: 10.1200/JCO.2015.62.1086. PMID: 26351353; PMCID: PMC4586167.
[14]. DIPRECE. Plan nacional de prevención y control del VIH/SIDA e ITS. [Internet] Vol. 1. 1ra ed. Santiago, Chile, 2018. Disponible en: https://diprece.minsal.cl/wp-content/uploads/2019/06/2019.06.12_PLAN-NACIONAL-VIH-SIDA-E-ITS.pdf.
[15]. INJUV. Novena Encuesta nacional de juventud 2018. [Internet] Vol 1., 1ra ed. Santiago, Chile; 2019. Disponible en: http://www.injuv.gob.cl/storage/docs/9%C2%B0_Encuesta_Nacional_de_Juventud_2018.pdf.
Published
2021-01-31
How to Cite
HERMOSILLA PIZARRO, Carolina et al.
Deintensification of radiotherapy in oropharyngeal carcinoma of squamous cells..
Journal of Oral Research, [S.l.], p. 1-5, jan. 2021.
ISSN 0719-2479.
Available at: <https://www.joralres.com/index.php/JOralRes/article/view/joralres.2021.037>. Date accessed: 20 apr. 2024.
doi: https://doi.org/10.17126/joralres.2021.037.
Section
Reviews
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. © 2024.
